Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

This study is testing a combination of two targeted drugs — osimertinib and savolitinib — for people with advanced non-small cell lung cancer (NSCLC) that has become resistant to prior treatments. The trial focuses on patients whose tumors have a low level of a gene amplification called MET, which may be driving their cancer's resistance. **You may be eligible if...** - You have advanced or metastatic NSCLC that has stopped responding to osimertinib, chemotherapy-immunotherapy, or anti-angiogenesis therapy - Your tumor has low MET amplification (fewer than 5 copies by FISH testing) - You are 18 or older and in reasonably good health - You have measurable tumor on imaging - Your kidneys, liver, and blood counts are functioning adequately **You may NOT be eligible if...** - You have significant heart rhythm problems or a prolonged QT interval on your electrocardiogram (ECG) - You have another serious uncontrolled illness - You are pregnant or not willing to use contraception Talk to your doctor to see if this trial is right for you.